BindingDB PrimarySearch

Found 8 hits Enz. Inhib. hit(s) with Target = 'Indoleamine 2,3-dioxygenase 1' and Ligand = 'BDBM310197'
Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	k_off s^-1	k_on M^-1s^-1	pH	Temp °C
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	US Patent	n/a	n/a	210	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc.; iTEOS THERAPEUTICS US Patent					Assay Description To measure enzymatic activity of human IDO1, the reaction mixture contained (final concentrations) potassium phosphate buffer (50 mM, pH 6.5), ascorb...				US Patent US10945994 (2021) BindingDB Entry DOI: 10.7270/Q25D8W03
Pfizer Inc.; iTEOS THERAPEUTICS US Patent					More data for this Ligand-Target Pair
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	US Patent	n/a	n/a	>1.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc.; iTEOS THERAPEUTICS US Patent					Assay Description To measure enzymatic activity of human IDO1, the reaction mixture contained (final concentrations) potassium phosphate buffer (50 mM, pH 6.5), ascorb...				US Patent US10945994 (2021) BindingDB Entry DOI: 10.7270/Q25D8W03
Pfizer Inc.; iTEOS THERAPEUTICS US Patent					More data for this Ligand-Target Pair
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	Article PubMed	n/a	n/a	1.30E+4	n/a	n/a	n/a	n/a	n/a	n/a
iTeos Therapeutics Curated by ChEMBL					Assay Description Inhibition of IDO-1 in IFN-gamma-stimulated human HeLa cells assessed as decrease in kynurenine production after 16 to 24 hrs by PDMAB method				J Med Chem 60: 9617-9629 (2017) Article DOI: 10.1021/acs.jmedchem.7b00974 BindingDB Entry DOI: 10.7270/Q2ZP48M3
iTeos Therapeutics Curated by ChEMBL					More data for this Ligand-Target Pair
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	Article PubMed	n/a	n/a	3.80E+4	n/a	n/a	n/a	n/a	n/a	n/a
iTeos Therapeutics Curated by ChEMBL					Assay Description Inhibition of human recombinant IDO-1 using tryptophan as substrate after 22 mins by LC-MS/MS method				J Med Chem 60: 9617-9629 (2017) Article DOI: 10.1021/acs.jmedchem.7b00974 BindingDB Entry DOI: 10.7270/Q2ZP48M3
iTeos Therapeutics Curated by ChEMBL					More data for this Ligand-Target Pair
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	US Patent	n/a	n/a	>5.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
University of Tampere					Assay Description The compounds of the present invention inhibit the enzymatic activity of human IDO1.To measure enzymatic activity of human IDO1, the reaction mixture...				J Med Chem 52: 646-54 (2009) BindingDB Entry DOI: 10.7270/Q2959KW7
University of Tampere					More data for this Ligand-Target Pair
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	US Patent	n/a	n/a	>5.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
ITEOS THERAPEUTICS US Patent					Assay Description To measure enzymatic activity of human IDO1, the reaction mixture contained (final concentrations) potassium phosphate buffer (50 mM, pH 6.5), ascorb...				US Patent US9603836 (2017) BindingDB Entry DOI: 10.7270/Q2MK6FZ8
ITEOS THERAPEUTICS US Patent					More data for this Ligand-Target Pair
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	US Patent	n/a	n/a	>5.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc.; iTEOS THERAPEUTICS US Patent					Assay Description To measure enzymatic activity of human IDO1, the reaction mixture contained (final concentrations) potassium phosphate buffer (50 mM, pH 6.5), ascorb...				US Patent US10945994 (2021) BindingDB Entry DOI: 10.7270/Q25D8W03
Pfizer Inc.; iTEOS THERAPEUTICS US Patent					More data for this Ligand-Target Pair
Indoleamine 2,3-dioxygenase 1 (Homo sapiens (Human))	BDBM310197 (US10945994, Compound 2a \| US9603836, Compound 2a \|...) Show SMILES Show InChI	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	Article PubMed	n/a	n/a	5.40E+4	n/a	n/a	n/a	n/a	n/a	n/a
iTeos Therapeutics Curated by ChEMBL					Assay Description Inhibition of human recombinant IDO-1 using L-Trp as substrate after 15 mins by PDMAB-based assay				J Med Chem 60: 9617-9629 (2017) Article DOI: 10.1021/acs.jmedchem.7b00974 BindingDB Entry DOI: 10.7270/Q2ZP48M3
iTeos Therapeutics Curated by ChEMBL					More data for this Ligand-Target Pair